retatrutide obesity phase 2 trial 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide study sees significant weight

Conclusion Concerns about Hims' GLP-1 strategy appear largely overblown The company is likely operating within legal boundaries and has a strong legal team Even if Novo sued for patent infringement, the most likely outcome would be a settlement with minimal negative impact In sum, it appears that concerns over the decision by Hims to continue to compound personalized versions of GLP-1 weight loss drugs past the enforcement deadlines set by the FDA are misplaced

Available via compounding pharmacy

Organic certification ensures the product is free from pesticides and other harmful chemicals that could irritate sensitive digestive tissues

[DOI] [PubMed] [Google Scholar] [108].Dushay J, Gao C, Gopalakrishnan GS, et al

PMID 38224592

JAMA 268 , 13141319 (1992)